» Articles » PMID: 12432570

1alpha,25-dihydroxyvitamin D3 Inhibits Anti-CD40 Plus IL-4-mediated IgE Production in Vitro

Overview
Journal Eur J Immunol
Date 2002 Nov 15
PMID 12432570
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

In the present study, we examined whether anti-CD40+IL-4-mediated B cell proliferation and immunoglobulin synthesis is affected by vitamin D (VD) and its low-hypercalcemic analogue EB1089 in Bcells from healthy donors. Analysis of vitamin D receptor (VDR) expression showed that only anti-CD40+IL-4-stimulated, but not resting B cells express VDR. Studies on B cell proliferation revealed that anti-CD40+IL-4-mediated proliferation of B cells was not affected by VD or EB1089. By contrast, IgE synthesis was markedly inhibited by both, VD and EB1089, starting at concentrations from 10(-10) M for VD and 10(-12) M for EB1089, with maximal inhibition at 10(-6) M (VD 85.5+/-9.7%; EB1089 77.3+/-10.8%). The production of the other Ig (IgA and IgG) was not significantly inhibited by VD after anti-CD40+IL-4 stimulation, and IgM production was only slightly reduced (18.7+/-7.9%). These observations were confirmed by intracellular staining of the different isotypes in B cells after anti-CD40+IL-4 stimulation, which showed a strong reduction of IgE(+) cells in the presence of VD. Analyses of molecules that are known to affect IgE production (CD23 and IL-6) revealed that these are not involved in VD-dependent inhibition of IgE production. By contrast, epsilon germ-line transcription was inhibited by VD (41.2+/-26.1%; n=5), as was NF-kappaB (p50 and p65) protein expression in stimulated cells. These data show that VD and its analogue EB1089 inhibit IgE production of anti-CD40+IL-4-stimulated B cells in vitro. The involved mechanism includes epsilon germ-line transcription, NF-kappaB activation and switch recombination suggesting that complex mechanisms of VD action in anti-CD40+IL-4-stimulated B cells are responsible.

Citing Articles

Clinical Diagnostic Value of Serum 25-Hydroxyvitamin D in Severe Fever with Thrombocytopenia Syndrome.

Liu T, Liu J, Wu J, Qin L, Shi Y, Qi Y Infect Drug Resist. 2023; 16:1715-1724.

PMID: 36999126 PMC: 10046179. DOI: 10.2147/IDR.S403482.


Antibody production in mice requires neither vitamin D, nor the vitamin D receptor.

Plum L, Blaser W, Peter L, Prahl J, Seeman J, Deluca H Front Immunol. 2022; 13:960405.

PMID: 36341456 PMC: 9631817. DOI: 10.3389/fimmu.2022.960405.


Vitamin D status can affect COVID-19 outcomes also in pediatric population.

Miraglia Del Giudice M, Indolfi C, Dinardo G, Decimo F, Decimo A, Klain A PharmaNutrition. 2022; 22:100319.

PMID: 36268528 PMC: 9562619. DOI: 10.1016/j.phanu.2022.100319.


Molecular mechanisms and therapeutic effects of different vitamins and minerals in COVID-19 patients.

Karami Fath M, Naderi M, Hamzavi H, Ganji M, Shabani S, Noorabad Ghahroodi F J Trace Elem Med Biol. 2022; 73:127044.

PMID: 35901669 PMC: 9297660. DOI: 10.1016/j.jtemb.2022.127044.


Vitamin D Deficiency, Osteoporosis and Effect on Autoimmune Diseases and Hematopoiesis: A Review.

De Martinis M, Allegra A, Sirufo M, Tonacci A, Pioggia G, Raggiunti M Int J Mol Sci. 2021; 22(16).

PMID: 34445560 PMC: 8396272. DOI: 10.3390/ijms22168855.